Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoMed TherapeuticsFRA:F98 -9.58%19 Days Payable is 384.36 as of Dec. 2025, which is 31% below its 10-year median of 553.86. GuruFocus rates FRA:F98 with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 702 Biotechnology companies, CytoMed Therapeutics ranks better than 77.07% on this metric.
The historical rank and industry rank for CytoMed Therapeutics's Days Payable or its related term are showing as below:
FRA:F98'
s Days Payable Range Over the Past 10 Years
Min: 430.34 Med: 553.86 Max: 673.85
Current: 430.34
During the past 6 years, CytoMed Therapeutics's highest Days Payable was 673.85. The lowest was 430.34. And the median was 553.86.
FRA:F98's Days Payable is ranked better than 77.07% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs FRA:F98: 430.34
CytoMed Therapeutics's Days Payable
declined
from Dec. 2024 (414.13) to Dec. 2025 (384.36).
It may suggest that CytoMed Therapeuticsaccelerated paying its suppliers.
CytoMed Therapeutics Days Payable Related Terms
CytoMed Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for CytoMed Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:F98 vs LEXX, INAB, TRAW: Days Payable Comparison
For the Biotechnology subindustry, CytoMed Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoMed Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where CytoMed Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
CytoMed Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoMed Therapeutics (FRA:F98) has a Days Payable of 384.36 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CytoMed Therapeutics and its competitors. This is 31% below median its historical median of 553.86. Over the past decade, CytoMed Therapeutics' Days Payable has ranged from 430.34 to 673.85. According to the industry distribution chart, CytoMed Therapeutics ranks #161 out of 702 companies in the Biotechnology industry, placing it in the top 22.9%.
Is CytoMed Therapeutics' Days Payable too high?
CytoMed Therapeutics' current Days Payable of 384.36 is 31% below median its 10-year median of 553.86. Over the past 10 years, this metric has ranged from a low of 430.34 to a high of 673.85. The Biotechnology industry median Days Payable is 113.10. CytoMed Therapeutics' value of 384.36 is 239.8% above this industry median. Based on the distribution chart, CytoMed Therapeutics ranks #161 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CytoMed Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' Days Payable compare to LEXX and INAB?
According to the Biotechnology industry distribution chart, CytoMed Therapeutics ranks #161 out of 702 companies for Days Payable. This places CytoMed Therapeutics in the top 23% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. CytoMed Therapeutics' value of 384.36 is 239.8% above this benchmark. Historically, CytoMed Therapeutics' own Days Payable has ranged from 430.34 to 673.85 over the past decade. While the company's 10-year median is 553.86 vs. the industry median of 113.10, CytoMed Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytoMed Therapeutics's current Days Payable of 384.36 is 239.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CytoMed Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoMed Therapeutics's current Days Payable is 384.36, which is 31% below median its own 10-year median of 553.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (FRA:F98) has a current Days Payable of 384.36. The current Days Payable is 384.36, which is 31% below median its 10-year median of 553.86 and 239.8% above the Biotechnology industry median of 113.10. CytoMed Therapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For CytoMed Therapeutics (FRA:F98), the current Days Payable is 384.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
19GF Score
Get the complete analysis for FRA:F98
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F98 has been successfully added to your 
